Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease.

John Koreth, Maria Carmen Martinez Munoz, Jeremy Pantin, Shukaib Arslan, Jaime Sanz, Alison Loren, Benedetta Rambaldi, Elisa Sala, Avichai Shimoni, Tsila Zuckerman, Corey Cutler, Lisette Acevedo, Kham Phenis, Eugene Sun, Stephen Connelly, Joel Rothman

Blood (2025) 146 (Supplement 1): 274.

https://doi.org/10.1182/blood-2025-274

Published: 2025

Journal Articles

Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT

Blood (2025) 146 (Supplement 1): 2526.

https://doi.org/10.1182/blood-2025-2526

Published: 2025

Journal Articles

Pulmonary function tests performed prior to CAR-T cell administration could be instrumental in predicting post-treatment pulmonary toxicity: A single-arm prospective study

Blood (2025) 146 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2025-2750

Published: 2025

Journal Articles

Abnormal adhesion of particular hematopoietic stem and progenitor cell subpopulations in the bone marrow, driven by aberrant interaction between VCAM-1 and VLA-4, ultimately contributes to leukemogenesis

Tsila Zuckerman, Irina Tikhonova, Maha Agbaria, Shlomit Yehudai-Reshef

Blood (2025) 146 (Supplement 1): 1372.

https://doi.org/10.1182/blood-2025-1372

Published: 2025

Journal Articles

T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy

Blood (2025) 146 (7): 834–846.

https://doi.org/10.1182/blood.2025028833

Published: 2025

Includes: Supplemental data

Journal Articles

Optical Genome Mapping Reclassifies Patients with Intermediate Risk Acute Myeloid Leukemia

Baher Krayem, Nivin moustafa-Hawash, Avraham Frisch, Christina Srouji, Tsila Zuckerman

Blood (2024) 144 (Supplement 1): 1559.

https://doi.org/10.1182/blood-2024-206768

Published: 2024

Journal Articles

Belumosudil Is Efficacious for the Management of Heavily Pretreated and Prolonged Chronic Graft-Versus-Host Disease: A Retrospective Multi-Center Real-World Study By the Israel Association for Bone Marrow Transplantation and Cellular Therapy

Ben Varon, Ron Ram, Avichai Shimoni, Batia Avni, Sigal Grisariu, Vered Stavi, Yael Bar-On, Moshe Yeshurun, Ronit Elhasid, Aharon Gefen, Asaf Yanir, Odelia Amit, Dana Yehudai-Ofir, Israel Henig, Tsila Zuckerman

Blood (2024) 144 (Supplement 1): 7338.

https://doi.org/10.1182/blood-2024-206874

Published: 2024

Journal Articles

The Ability of Currently Used Scoring Systems to Predict 30 and 100-Days Non-Relapse Mortality Among Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Amir Tafesh, Dana Yehudai-Ofir, Ofrat Beyar-Katz, Hazim Khatib, Baher Krayem, Avraham Frisch, Tsila Zuckerman, Israel Henig

Blood (2024) 144 (Supplement 1): 3482.

https://doi.org/10.1182/blood-2024-194308

Published: 2024

Journal Articles

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 608.

https://doi.org/10.1182/blood-2024-207638

Published: 2024

Journal Articles

Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1748.

https://doi.org/10.1182/blood-2024-202937

Published: 2024

Journal Articles

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

Blood (2024) 144 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2024-203871

Published: 2024

Journal Articles

Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Blood (2024) 144 (Supplement 1): 965.

https://doi.org/10.1182/blood-2024-205669

Published: 2024

Journal Articles

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Blood (2024) 144 (Supplement 1): 912.

https://doi.org/10.1182/blood-2024-203520

Published: 2024

Journal Articles

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2024-200050

Published: 2024

Journal Articles

For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious

Baher Krayem, Avraham Frisch, Tsila Zuckerman, Israel Henig, Dana Yehudai-Ofir, Boaz Nachmias, Hazim Khatib, Arnon Haran, Shlomzion Aumann

Blood (2024) 144 (Supplement 1): 4269.

https://doi.org/10.1182/blood-2024-204627

Published: 2024

Journal Articles

Soluble LAG3: A Potential Marker for the Development and Activity of Acute Graft-Versus-Host Disease

Dana Yehudai-Ofir, Nasren Eiza, Israel J. Henig, Tsila Zuckerman, Zahava Vadasz

Blood (2023) 142 (Supplement 1): 4795.

https://doi.org/10.1182/blood-2023-184496

Published: 2023

Journal Articles

AML Drug Tolerant Persister (DTP) Cells Survive Chemotherapy By Transiently Altering Cellular Lipidomics to Increase Plasma Membrane Rigidity, but Also Increases Sensitivity to Immune Cell Killing

Yael Morgenstern, JongBok Lee, Yoosu Na, William Gwynne, Rose Hurren, Li Ma, Marcela Gronda, Chaitra Sarathy, Arvind Mer, Andrea Arruda, Avraham Frisch, Tsila Zuckerman, Yishai Ofran, Mark D. Minden, Li Zhang, Catherine O'Brien, J. Rafael Montenegro-Burke, Aaron D. Schimmer

Blood (2023) 142 (Supplement 1): 2806.

https://doi.org/10.1182/blood-2023-178995

Published: 2023

Journal Articles

Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching

Gil Fridberg, Odelia Amit, Liat Shargian, Ofrat Beyar Katz, Sigal Grisariu, Chava Perry, Ronit Gurion, Batia Avni, Tsila Zuckerman, Irit Avivi Mazza, Ron Ram

Blood (2023) 142 (Supplement 1): 4886.

https://doi.org/10.1182/blood-2023-188473

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation with Treosulfan -Fludarabine and Busulfan-Fludarabine Conditioning Have Similar Efficacy in Patients ≥65 Years Old or Those with Comorbidities

Israel J. Henig, Ohad Geller, Dana Yehudai-Ofir, Baher Krayem, Avraham Frisch, Hazim Khatib, Tsila Zuckerman

Blood (2023) 142 (Supplement 1): 2166.

https://doi.org/10.1182/blood-2023-180721

Published: 2023

Journal Articles

The ELN 2022 Risk Stratification Has No Impact on the Dismal Prognosis of Patients with Acute Undifferentiated Leukemia

Baher Krayem, Tsila Zuckerman, Avraham Frisch, Ilana Slouzkey, Tehila Azoulay, Michal Karmona, Liran I. Shlush, Nathali Kaushansky, Noa Chapal-Ilani, Shimrit Ringelstein-Harlev

Blood (2023) 142 (Supplement 1): 4221.

https://doi.org/10.1182/blood-2023-188592

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease.

Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT

Pulmonary function tests performed prior to CAR-T cell administration could be instrumental in predicting post-treatment pulmonary toxicity: A single-arm prospective study

Abnormal adhesion of particular hematopoietic stem and progenitor cell subpopulations in the bone marrow, driven by aberrant interaction between VCAM-1 and VLA-4, ultimately contributes to leukemogenesis

T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy

Optical Genome Mapping Reclassifies Patients with Intermediate Risk Acute Myeloid Leukemia

Belumosudil Is Efficacious for the Management of Heavily Pretreated and Prolonged Chronic Graft-Versus-Host Disease: A Retrospective Multi-Center Real-World Study By the Israel Association for Bone Marrow Transplantation and Cellular Therapy

The Ability of Currently Used Scoring Systems to Predict 30 and 100-Days Non-Relapse Mortality Among Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious

Soluble LAG3: A Potential Marker for the Development and Activity of Acute Graft-Versus-Host Disease

AML Drug Tolerant Persister (DTP) Cells Survive Chemotherapy By Transiently Altering Cellular Lipidomics to Increase Plasma Membrane Rigidity, but Also Increases Sensitivity to Immune Cell Killing

Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching

Allogeneic Hematopoietic Stem Cell Transplantation with Treosulfan -Fludarabine and Busulfan-Fludarabine Conditioning Have Similar Efficacy in Patients ≥65 Years Old or Those with Comorbidities

The ELN 2022 Risk Stratification Has No Impact on the Dismal Prognosis of Patients with Acute Undifferentiated Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only